Skip to content

Artificial Endometrial Preparation for Frozen Thawed Embryo Transfer Applying Either Endometrin or Utrogestan

Artificial Endometrial Preparation for Frozen Thawed Embryo Transfer Applying Either Endometrin or Utrogestan - a Clinical Comparative Study

Status
Suspended
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00345306
Enrollment
120
Registered
2006-06-28
Start date
2007-03-31
Completion date
Unknown
Last updated
2008-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frozen Thawed Embryo Transfer

Keywords

endometrial preparation, Utrogestan, Endometrin

Brief summary

The transfer of frozen-thawed embryos can be performed in a natural ovulatory cycle or in a hormonally manipulated cycle with a comparable pregnancy rate of 15%-20% per ET. When a hormonally modulated ET cycle is scheduled,an artificial endometrial preparation is carried out using estrogen stimulation followed by a concomitant progesterone treatment. Two progestative drugs are currently used in conventional IVF treatment, Utrogetan and Endometrin. Although Endometrin has been be efficiently used to support the luteal phase after embryo transfer in IVF cycles, currently, there is no study that assess its efficacy for clinical use in frozen-thawed ET cycles. The present study aims to compare the outcome of frozen thawed ET cycles when either Endometrin or Utrogestan are used as the progestative substitution in an artificially prepared endometrium.

Interventions

DRUGComparison between two different progesterone administration

Sponsors

Hadassah Medical Organization
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years

Inclusion criteria

1. Patients undergoing frozen thawed ET cycles 2. Patient has at least two embryos suitable for transfer after thawing 3. Age 18-35 years -

Exclusion criteria

1. Any known sensitivity to Endometrin or Utrogestan 2. Endometrial thickness less than 7.5 mm after estrogen priming -

Design outcomes

Primary

MeasureTime frame
Pregnancy rates

Secondary

MeasureTime frame
Lutheal hormonal profile

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026